ImmunoGen and Lilly unite to develop cancer treatments

12/20/2011 | Wall Street Journal, The

ImmunoGen and Eli Lilly and Co. agreed to jointly develop antibody-based cancer drugs in a deal worth at least $20 million. The agreement gives Lilly exclusive licensing rights to some of ImmunoGen's cancer drugs in exchange for a $200 million milestone fee for each drug licensed as well as royalties on any product developed through the partnership. Maytansinoid targeted antibody payload technology developed by ImmunoGen delivers drugs straight to cancer cells.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN